Literature DB >> 8115160

Severity of scleritis and episcleritis.

M Sainz de la Maza1, N S Jabbur, C S Foster.   

Abstract

PURPOSE: Inflammation of the wall of the eyeball may extend to adjacent ocular tissues with blinding consequences and may be associated with potentially lethal systemic disorders. This study was undertaken to evaluate the ocular complications and systemic disease associations of the different types of scleritis and episcleritis.
METHODS: Ocular complications and specific disease association were evaluated in 266 patients (358 eyes) with different types of scleritis (diffuse, nodular, necrotizing, scleromalacia perforans, and posterior) and episcleritis (simple and nodular).
RESULTS: In patients with scleritis, decrease in vision occurred in 37%, anterior uveitis was present in 42%, peripheral ulcerative keratitis developed in 14%, glaucoma occurred in 13%, cataract formed in 17%, fundus abnormalities appeared in 6%, and specific disease association was uncovered in 57%. These findings were most commonly associated with necrotizing scleritis. In patients with episcleritis, decreased vision occurred in 2%, anterior uveitis was present in 11%, glaucoma developed in 4%, cataract formed in 2%, and specific disease association was uncovered in 32%. These findings were similar in simple and nodular episcleritis.
CONCLUSIONS: In a patient with scleritis, examination of visual acuity, anterior uvea, cornea, lens, intraocular pressure, and fundus must be performed in every follow-up visit, and a meticulous approach for detection of a specific associated disease must be undertaken since the first visit. Scleritis is more severe than episcleritis, and necrotizing scleritis is the most severe type of scleritis. Classification of scleritis and episcleritis provides valuable prognostic information.

Entities:  

Mesh:

Year:  1994        PMID: 8115160     DOI: 10.1016/s0161-6420(94)31325-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  46 in total

1.  Ophthaproblem.

Authors:  Khalid Hasanee; Sanjay Sharma
Journal:  Can Fam Physician       Date:  2003-08       Impact factor: 3.275

2.  Use of autologous fascia lata as a natural biomaterial for tectonic support in surgically induced necrotizing scleritis.

Authors:  H Kobtan
Journal:  Eye (Lond)       Date:  2015-01-30       Impact factor: 3.775

3.  Ocular hypertension and glaucoma incidence in patients with scleritis.

Authors:  Carsten Heinz; Nadine Bograd; Joerg Koch; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-07-22       Impact factor: 3.117

4.  Haemophilus influenzae associated scleritis.

Authors:  S O Sykes; C Riemann; C I Santos; D M Meisler; C Y Lowder; J P Whitcher; E T Cunningham
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

5.  Clinical features and visual outcomes of scleritis patients presented to tertiary care eye centers in Saudi Arabia.

Authors:  Mohammad Al Barqi; Ashley Behrens; Abdullah M Alfawaz
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

Review 6.  [Diagnosis and treatment of episcleritis and scleritis].

Authors:  C Tappeiner; K Walscheid; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2016-09       Impact factor: 1.059

7.  Infectious scleritis mimicking severe ocular inflammation: atypical initial presentation.

Authors:  Somasheila I Murthy; Alok Sati; Virender Sangwan
Journal:  BMJ Case Rep       Date:  2013-02-20

Review 8.  Ocular complications of childhood rheumatic diseases: nonuveitic inflammatory eye diseases.

Authors:  Andreas Reiff
Journal:  Curr Rheumatol Rep       Date:  2009-07       Impact factor: 4.592

9.  Clinical features, predisposing factors, and treatment outcomes of scleritis in the Korean population.

Authors:  Seong Joon Ahn; Joo Youn Oh; Mee Kum Kim; Jin Hak Lee; Won Ryang Wee
Journal:  Korean J Ophthalmol       Date:  2010-11-23

Review 10.  Scleritis and peripheral ulcerative keratitis.

Authors:  Anat Galor; Jennifer E Thorne
Journal:  Rheum Dis Clin North Am       Date:  2007-11       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.